AU743855B2 - Cancer immunotherapy using tumor cells combined with mixed lymphocytes - Google Patents
Cancer immunotherapy using tumor cells combined with mixed lymphocytes Download PDFInfo
- Publication number
- AU743855B2 AU743855B2 AU48242/97A AU4824297A AU743855B2 AU 743855 B2 AU743855 B2 AU 743855B2 AU 48242/97 A AU48242/97 A AU 48242/97A AU 4824297 A AU4824297 A AU 4824297A AU 743855 B2 AU743855 B2 AU 743855B2
- Authority
- AU
- Australia
- Prior art keywords
- cells
- tumor
- human
- lymphocytes
- allogeneic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000004698 lymphocyte Anatomy 0.000 title claims description 204
- 210000004881 tumor cell Anatomy 0.000 title claims description 152
- 238000002619 cancer immunotherapy Methods 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims description 627
- 206010028980 Neoplasm Diseases 0.000 claims description 284
- 230000000735 allogeneic effect Effects 0.000 claims description 148
- 239000000203 mixture Substances 0.000 claims description 129
- 238000000034 method Methods 0.000 claims description 87
- 239000000427 antigen Substances 0.000 claims description 79
- 108091007433 antigens Proteins 0.000 claims description 79
- 102000036639 antigens Human genes 0.000 claims description 79
- 102000004127 Cytokines Human genes 0.000 claims description 60
- 108090000695 Cytokines Proteins 0.000 claims description 60
- 238000011282 treatment Methods 0.000 claims description 57
- 230000004044 response Effects 0.000 claims description 56
- 230000028993 immune response Effects 0.000 claims description 47
- 210000000265 leukocyte Anatomy 0.000 claims description 45
- 230000002163 immunogen Effects 0.000 claims description 43
- 238000002560 therapeutic procedure Methods 0.000 claims description 30
- 230000000638 stimulation Effects 0.000 claims description 28
- 238000002360 preparation method Methods 0.000 claims description 27
- 230000000259 anti-tumor effect Effects 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 230000028327 secretion Effects 0.000 claims description 17
- 230000004936 stimulating effect Effects 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 238000012258 culturing Methods 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 9
- 238000001356 surgical procedure Methods 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 7
- 201000001441 melanoma Diseases 0.000 claims description 7
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 239000003226 mitogen Substances 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 claims 1
- 102100020880 Kit ligand Human genes 0.000 claims 1
- 241000209094 Oryza Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 description 78
- 230000000694 effects Effects 0.000 description 71
- 201000011510 cancer Diseases 0.000 description 63
- 241000699670 Mus sp. Species 0.000 description 55
- 108090000978 Interleukin-4 Proteins 0.000 description 42
- 102000004388 Interleukin-4 Human genes 0.000 description 41
- 238000003556 assay Methods 0.000 description 41
- 238000004242 micellar liquid chromatography Methods 0.000 description 31
- 238000012360 testing method Methods 0.000 description 30
- 208000002839 megalencephalic leukoencephalopathy with subcortical cysts Diseases 0.000 description 28
- 108010002350 Interleukin-2 Proteins 0.000 description 26
- 102000000588 Interleukin-2 Human genes 0.000 description 26
- 229940030156 cell vaccine Drugs 0.000 description 24
- 239000007943 implant Substances 0.000 description 24
- 210000004988 splenocyte Anatomy 0.000 description 24
- 102100040247 Tumor necrosis factor Human genes 0.000 description 23
- 208000005017 glioblastoma Diseases 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 108090000371 Esterases Proteins 0.000 description 21
- 210000001744 T-lymphocyte Anatomy 0.000 description 21
- 230000004913 activation Effects 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 21
- 238000002347 injection Methods 0.000 description 21
- 239000007924 injection Substances 0.000 description 21
- CHADEQDQBURGHL-UHFFFAOYSA-N (6'-acetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 CHADEQDQBURGHL-UHFFFAOYSA-N 0.000 description 20
- 210000005087 mononuclear cell Anatomy 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 19
- 238000002513 implantation Methods 0.000 description 18
- 238000002595 magnetic resonance imaging Methods 0.000 description 18
- 206010025323 Lymphomas Diseases 0.000 description 17
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 17
- 239000013598 vector Substances 0.000 description 17
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 16
- 230000035755 proliferation Effects 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 16
- 230000008901 benefit Effects 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 230000004083 survival effect Effects 0.000 description 15
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 14
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 14
- 239000012894 fetal calf serum Substances 0.000 description 14
- 238000009169 immunotherapy Methods 0.000 description 14
- 230000009467 reduction Effects 0.000 description 14
- 238000013459 approach Methods 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 12
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 12
- 238000000684 flow cytometry Methods 0.000 description 12
- 230000004077 genetic alteration Effects 0.000 description 12
- 231100000118 genetic alteration Toxicity 0.000 description 12
- 239000001963 growth medium Substances 0.000 description 12
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 12
- 230000009885 systemic effect Effects 0.000 description 12
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 11
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 11
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 11
- 238000005119 centrifugation Methods 0.000 description 11
- 230000001900 immune effect Effects 0.000 description 11
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 11
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 11
- 230000001177 retroviral effect Effects 0.000 description 11
- 230000004614 tumor growth Effects 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 230000001413 cellular effect Effects 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000002512 chemotherapy Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 230000003248 secreting effect Effects 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 206010003571 Astrocytoma Diseases 0.000 description 9
- 206010027476 Metastases Diseases 0.000 description 9
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 9
- 230000006023 anti-tumor response Effects 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 229960001380 cimetidine Drugs 0.000 description 9
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 206010061289 metastatic neoplasm Diseases 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 238000002271 resection Methods 0.000 description 9
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 9
- 238000002255 vaccination Methods 0.000 description 9
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 8
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 230000036039 immunity Effects 0.000 description 8
- 230000001394 metastastic effect Effects 0.000 description 8
- 210000005259 peripheral blood Anatomy 0.000 description 8
- 239000011886 peripheral blood Substances 0.000 description 8
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 8
- 230000001988 toxicity Effects 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 208000003174 Brain Neoplasms Diseases 0.000 description 7
- 206010018338 Glioma Diseases 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 7
- 229960001340 histamine Drugs 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 230000002601 intratumoral effect Effects 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000001959 radiotherapy Methods 0.000 description 7
- 230000009257 reactivity Effects 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- 208000032612 Glial tumor Diseases 0.000 description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 6
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000004748 cultured cell Anatomy 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 238000002825 functional assay Methods 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 229960004857 mitomycin Drugs 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 5
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 5
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 230000024932 T cell mediated immunity Effects 0.000 description 5
- 230000005809 anti-tumor immunity Effects 0.000 description 5
- 230000035584 blastogenesis Effects 0.000 description 5
- 230000007969 cellular immunity Effects 0.000 description 5
- 230000001461 cytolytic effect Effects 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 230000005714 functional activity Effects 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 210000002443 helper t lymphocyte Anatomy 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 230000008105 immune reaction Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000002779 inactivation Effects 0.000 description 5
- 230000036512 infertility Effects 0.000 description 5
- 208000032839 leukemia Diseases 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 230000001613 neoplastic effect Effects 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 230000000306 recurrent effect Effects 0.000 description 5
- DWZAJFZEYZIHPO-UHFFFAOYSA-N santin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(O)C(OC)=C(O)C=C2O1 DWZAJFZEYZIHPO-UHFFFAOYSA-N 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000012224 working solution Substances 0.000 description 5
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000204031 Mycoplasma Species 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 208000007452 Plasmacytoma Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 230000000961 alloantigen Effects 0.000 description 4
- 230000005975 antitumor immune response Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 230000036755 cellular response Effects 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000016396 cytokine production Effects 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000017307 interleukin-4 production Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 125000003831 tetrazolyl group Chemical group 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 201000009030 Carcinoma Diseases 0.000 description 3
- 206010057248 Cell death Diseases 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 3
- 108010075704 HLA-A Antigens Proteins 0.000 description 3
- 208000037564 High-grade astrocytoma Diseases 0.000 description 3
- 206010060708 Induration Diseases 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 206010064912 Malignant transformation Diseases 0.000 description 3
- 206010027458 Metastases to lung Diseases 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010054094 Tumour necrosis Diseases 0.000 description 3
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 206010002224 anaplastic astrocytoma Diseases 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000003969 blast cell Anatomy 0.000 description 3
- 229960001714 calcium phosphate Drugs 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- -1 haptens Chemical class 0.000 description 3
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000036212 malign transformation Effects 0.000 description 3
- 238000013411 master cell bank Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 210000000869 occipital lobe Anatomy 0.000 description 3
- 238000011275 oncology therapy Methods 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 208000037821 progressive disease Diseases 0.000 description 3
- 230000007115 recruitment Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- 230000005951 type IV hypersensitivity Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000711404 Avian avulavirus 1 Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 206010048962 Brain oedema Diseases 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 2
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 2
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000003814 Interleukin-10 Human genes 0.000 description 2
- 108090000174 Interleukin-10 Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- 102000000704 Interleukin-7 Human genes 0.000 description 2
- ZDLDXNCMJBOYJV-YFKPBYRVSA-N L-arginine, methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N ZDLDXNCMJBOYJV-YFKPBYRVSA-N 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 102100025136 Macrosialin Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 208000007660 Residual Neoplasm Diseases 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 206010045240 Type I hypersensitivity Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003302 anti-idiotype Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 208000006752 brain edema Diseases 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000000981 bystander Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 231100000313 clinical toxicology Toxicity 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012321 colectomy Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 210000000448 cultured tumor cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011334 debulking surgery Methods 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- SXHBILQYQWZSIW-UHFFFAOYSA-L disodium;4-[3,5-dimethyl-n-(4-sulfonatobutyl)anilino]butane-1-sulfonate Chemical compound [Na+].[Na+].CC1=CC(C)=CC(N(CCCCS([O-])(=O)=O)CCCCS([O-])(=O)=O)=C1 SXHBILQYQWZSIW-UHFFFAOYSA-L 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012595 freezing medium Substances 0.000 description 2
- 210000001652 frontal lobe Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 208000002409 gliosarcoma Diseases 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 208000029824 high grade glioma Diseases 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 102000055229 human IL4 Human genes 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 230000005934 immune activation Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 201000011614 malignant glioma Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 2
- 238000000275 quality assurance Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 208000018316 severe headache Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 229940038237 tumor antigen vaccine Drugs 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 230000037455 tumor specific immune response Effects 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- ASPDJZINBYYZRU-UHFFFAOYSA-N 5-amino-2-chlorobenzotrifluoride Chemical compound NC1=CC=C(Cl)C(C(F)(F)F)=C1 ASPDJZINBYYZRU-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 102000038504 B7-1 Antigen Human genes 0.000 description 1
- 108010035053 B7-1 Antigen Proteins 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 108010003639 CD56 Antigen Proteins 0.000 description 1
- 102000004652 CD56 Antigen Human genes 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000581444 Clinidae Species 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 229940122601 Esterase inhibitor Drugs 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
- 101000759926 Homo sapiens Ubiquitin carboxyl-terminal hydrolase isozyme L1 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 1
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 102100023123 Mucin-16 Human genes 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 201000001718 Roberts syndrome Diseases 0.000 description 1
- 208000012474 Roberts-SC phocomelia syndrome Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010068771 Soft tissue neoplasm Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 101500017934 Sus scrofa Saposin-B Proteins 0.000 description 1
- 101150057615 Syn gene Proteins 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 206010045170 Tumour lysis syndrome Diseases 0.000 description 1
- 102100025038 Ubiquitin carboxyl-terminal hydrolase isozyme L1 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000690 anti-lymphoma Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000012209 assay specification Methods 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 201000003714 breast lobular carcinoma Diseases 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000005889 cellular cytotoxicity Effects 0.000 description 1
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000011500 cytoreductive surgery Methods 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- WSFSSNUMVMOOMR-DICFDUPASA-N dideuteriomethanone Chemical compound [2H]C([2H])=O WSFSSNUMVMOOMR-DICFDUPASA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000002710 external beam radiation therapy Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 208000028149 female reproductive system neoplasm Diseases 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000005161 hepatic lobe Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 238000013339 in-process testing Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012913 medium supplement Substances 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006680 metabolic alteration Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940023146 nucleic acid vaccine Drugs 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 210000001152 parietal lobe Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000021670 response to stimulus Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000005001 rutherford backscattering spectroscopy Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 238000007801 sublethal irradiation Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229940030325 tumor cell vaccine Drugs 0.000 description 1
- 208000010380 tumor lysis syndrome Diseases 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/13—Tumour cells, irrespective of tissue of origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2854896P | 1996-10-11 | 1996-10-11 | |
| US60/028548 | 1996-10-11 | ||
| PCT/US1997/018718 WO1998016238A2 (en) | 1996-10-11 | 1997-10-10 | Cancer immunotherapy using tumor cells combined with mixed lymphocytes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU4824297A AU4824297A (en) | 1998-05-11 |
| AU743855B2 true AU743855B2 (en) | 2002-02-07 |
Family
ID=21844058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU48242/97A Ceased AU743855B2 (en) | 1996-10-11 | 1997-10-10 | Cancer immunotherapy using tumor cells combined with mixed lymphocytes |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6207147B1 (enExample) |
| EP (1) | EP0930887B1 (enExample) |
| JP (1) | JP2001509135A (enExample) |
| KR (1) | KR20000049096A (enExample) |
| CN (1) | CN1237909A (enExample) |
| AR (1) | AR004445A1 (enExample) |
| AT (1) | ATE229810T1 (enExample) |
| AU (1) | AU743855B2 (enExample) |
| BR (1) | BR9712988A (enExample) |
| CA (1) | CA2267157C (enExample) |
| DE (1) | DE69718029T2 (enExample) |
| NO (1) | NO991691L (enExample) |
| WO (1) | WO1998016238A2 (enExample) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080220025A1 (en) * | 1995-03-17 | 2008-09-11 | James Thompson | Treating Tumors Using Implants Comprising Combinations of Allogeneic Cells |
| US7361332B2 (en) | 1995-03-17 | 2008-04-22 | The Regents Of The University Of California | Treating tumors using implants comprising combinations of allogeneic cells |
| AU7154598A (en) * | 1997-04-23 | 1998-11-13 | Regents Of The University Of California, The | A cell strain with activated anti-cancer cytotoxic activity |
| DE69837552D1 (de) | 1997-10-10 | 2007-05-24 | Univ California | Allogene zellkombination enthaltende implantate zur krebsbehandlung |
| WO1999019462A1 (en) * | 1997-10-10 | 1999-04-22 | The Regents Of The University Of California | Enhanced immunogenic cell populations prepared using h2 receptor antagonists |
| DE69820291D1 (de) | 1997-10-10 | 2004-01-15 | Meyer Pharmaceuticals Llc | Krebsimmuntherapie mittels allostimulierten zellen zur sequentiellen implantationsstrategie |
| JP4389039B2 (ja) * | 1998-04-09 | 2009-12-24 | 株式会社リンフォテック | アロジェニックな活性化ｃｄ４陽性細胞を主成分とする医薬組成物、およびその製造方法、ならびに該医薬組成物調製用キット |
| US7666609B1 (en) | 1998-12-01 | 2010-02-23 | Shanghai Cp Guojian Pharmaceutical Co. Ltd. | Method and composition for diagnosis of melanocytic lesions |
| EP1159967B1 (en) * | 1999-02-09 | 2008-09-10 | Riken | Tumor vaccines |
| US7303911B2 (en) | 2000-04-01 | 2007-12-04 | Onyvax Limited | Prostate cell lines |
| US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| US20080194022A1 (en) * | 2000-08-03 | 2008-08-14 | Clarke Michael F | Isolation and use of solid tumor stem cells |
| US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
| DE10043437A1 (de) * | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| US7723111B2 (en) * | 2001-03-09 | 2010-05-25 | The United States Of America As Represented By The Department Of Health And Human Services | Activated dual specificity lymphocytes and their methods of use |
| ATE500808T1 (de) * | 2001-05-11 | 2011-03-15 | Wellstat Biologics Corp | Onkolytische virustherapie |
| US7658926B2 (en) * | 2001-09-14 | 2010-02-09 | Opexa Pharmaceuticals, Inc. | Autologous T-cell vaccines materials and methods |
| EP1293205A1 (en) * | 2001-09-18 | 2003-03-19 | G2M Cancer Drugs AG | Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease |
| CA2469135A1 (en) * | 2001-11-27 | 2003-06-05 | Nexyte Ab | Production of eukaryotic proteins and nucleic acid molecules in c. elegans |
| KR20020060643A (ko) * | 2002-06-04 | 2002-07-18 | 김진경 | 타인의 면역시스템을 이용하는 암의 치료 방법 |
| AU2003258090B2 (en) * | 2002-08-08 | 2010-07-22 | Baylor College Of Medicine | Isolation and identification of T cells |
| US7571817B2 (en) * | 2002-11-06 | 2009-08-11 | Varco I/P, Inc. | Automatic separator or shaker with electromagnetic vibrator apparatus |
| WO2004075855A2 (en) | 2003-02-26 | 2004-09-10 | Biomed Solutions, Llc | Process for in vivo treatment of specific biological targets in bodily fluid |
| WO2004096244A1 (en) * | 2003-05-02 | 2004-11-11 | Md Bioalpha Co. Ltd. | Method of preparing tumor vaccine for the inducement of anti-tumor activity and a pharmaceutical composition containing the same |
| EP1641491B1 (en) | 2003-06-11 | 2008-01-02 | University of Chicago | Increased t-cell tumor infiltration by mutant light |
| US7811983B2 (en) * | 2003-06-11 | 2010-10-12 | The University Of Chicago | Increased T-cell tumor infiltration and eradication of metastases by mutant light |
| US20050019336A1 (en) | 2003-07-23 | 2005-01-27 | Dalgleish Angus George | Human prostate cell lines in cancer treatment |
| US7696322B2 (en) * | 2003-07-28 | 2010-04-13 | Catalent Pharma Solutions, Inc. | Fusion antibodies |
| SG146691A1 (en) * | 2003-10-08 | 2008-10-30 | Vet Stem Inc | Methods of preparing and using stem cell compositions and kits comprising the same |
| US8029454B2 (en) | 2003-11-05 | 2011-10-04 | Baxter International Inc. | High convection home hemodialysis/hemofiltration and sorbent system |
| US20050112684A1 (en) * | 2003-11-21 | 2005-05-26 | Eric Holzle | Class I and Class II MHC Profiling for Social and Sexual Matching of Human Partners |
| ES2383306T3 (es) | 2004-02-03 | 2012-06-20 | The Regents Of The University Of Michigan | Composiciones para el tratamiento del cáncer de mama y de páncreas |
| US7858323B2 (en) | 2004-06-09 | 2010-12-28 | The Regents Of The University Of Michigan | Phage microarray profiling of the humoral response to disease |
| US8257715B1 (en) | 2004-08-26 | 2012-09-04 | University Of Notre Dame | Tissue vaccines and uses thereof |
| US9155789B2 (en) * | 2005-04-25 | 2015-10-13 | New York University | Use of allogenic or syngenic major histocompatibility complex (MHC) molecules as universal adjuvants for vaccines against neoplastic disease, infection and autoimmune disease |
| US20090162405A1 (en) * | 2006-12-14 | 2009-06-25 | Yong Qian | Proteinase-engineered cancer vaccine induces immune responses to prevent cancer and to systemically kill cancer cells |
| US8778362B2 (en) | 2005-10-27 | 2014-07-15 | University Of Notre Dame | Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof |
| US8802113B2 (en) * | 2005-10-27 | 2014-08-12 | University Of Notre Dame | Extracellular matrix cancer vaccine adjuvant |
| US8778360B2 (en) * | 2005-10-27 | 2014-07-15 | University Of Notre Dame | Extracellular matrix cancer vaccine adjuvant |
| US9308252B2 (en) * | 2005-10-27 | 2016-04-12 | Cook Biotech, Inc. | Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins |
| ES2641087T3 (es) | 2005-10-31 | 2017-11-07 | Oncomed Pharmaceuticals, Inc. | Composiciones y métodos para el diagnóstico y el tratamiento del cáncer |
| WO2007053648A2 (en) * | 2005-10-31 | 2007-05-10 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| WO2008121102A2 (en) * | 2006-02-21 | 2008-10-09 | The Regents Of The University Of Michigan | Hedgehog signaling pathway antagonist cancer treatment |
| WO2007100640A2 (en) * | 2006-02-21 | 2007-09-07 | The Regents Of The University Of Michigan | Growth hormone receptor antagonist cancer treatment |
| ES2553192T3 (es) * | 2006-05-05 | 2015-12-04 | Opexa Therapeutics | Vacuna de células T |
| ES2613957T3 (es) | 2006-08-04 | 2017-05-29 | Medimmune Limited | Anticuerpos contra ERBB2 |
| US7972594B2 (en) * | 2006-11-13 | 2011-07-05 | Immunovative Therapies Ltd. | Ablative immunotherapy |
| WO2008061392A1 (en) * | 2006-11-22 | 2008-05-29 | Hua Liu | Method for preparing cell populations with anti-tumor immune response activity |
| US20080147007A1 (en) * | 2006-12-19 | 2008-06-19 | Toby Freyman | Delivery device with pressure control |
| EP2106439B1 (en) | 2007-01-24 | 2014-11-12 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
| WO2008092153A2 (en) | 2007-01-26 | 2008-07-31 | University Of Louisville Research Foundation, Inc. | Modification of exosomal components for use as a vaccine |
| US20090093429A1 (en) * | 2007-02-08 | 2009-04-09 | Yang-Xin Fu | Combination therapy for treating cancer |
| EP2650018A3 (en) | 2007-05-14 | 2014-09-03 | The University of Chicago | Antibody-LIGHT fusion products for cancer therapeutics |
| CN101855549A (zh) * | 2007-09-12 | 2010-10-06 | 耶达研究及发展有限公司 | 在免疫豁免部位内治疗肿瘤的方法 |
| US8114276B2 (en) | 2007-10-24 | 2012-02-14 | Baxter International Inc. | Personal hemodialysis system |
| US9283266B2 (en) * | 2008-02-28 | 2016-03-15 | University Of Notre Dame | Metastasis inhibition preparations and methods |
| AU2009296246B2 (en) | 2008-09-26 | 2015-07-30 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| CA2779436A1 (en) * | 2008-10-31 | 2010-05-06 | Biogen Idec Ma Inc. | Light targeting molecules and uses thereof |
| JP5716180B2 (ja) | 2008-11-11 | 2015-05-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 抗ｃｘｃｒ１組成物および方法 |
| CU23740A1 (es) * | 2009-09-29 | 2011-12-28 | Ct Ingenieria Genetica Biotech | Método de obtención de una formulación de antígenos del virus de la hepatitis b |
| KR20120093978A (ko) * | 2009-10-27 | 2012-08-23 | 이뮤니쿰 에이비 | 항원 특이적 ｔ 세포의 증식 방법 |
| DK2510084T3 (da) * | 2009-12-08 | 2020-04-27 | The Board Of Trustees Of The Univ Of Illionis | Stamcelleimmunmoduleringsanvendelsesfremgangsmåder og apparat |
| US8846059B2 (en) | 2009-12-08 | 2014-09-30 | University Of Notre Dame | Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer |
| US20110150934A1 (en) * | 2009-12-18 | 2011-06-23 | University Of Notre Dame | Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| US20110237461A1 (en) * | 2010-03-17 | 2011-09-29 | The Regents Of The University Of Michigan | Using phage epitopes to profile the immune response |
| JP2013530929A (ja) | 2010-04-01 | 2013-08-01 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ｆｒｉｚｚｌｅｄ結合剤およびその使用 |
| WO2011129348A1 (ja) * | 2010-04-13 | 2011-10-20 | 株式会社Ｒｅｉメディカル | 癌組織由来細胞塊または癌細胞凝集塊から得られる癌治療用組成物およびそれを用いた免疫療法剤の製造方法ならびに免疫療法効果評価方法 |
| KR20140099328A (ko) | 2011-05-03 | 2014-08-11 | 이뮤노베이티브 테라피스, 엘티디. | 생세포를 포함하는 생물학적 약물을 처리하기 위한 용기 또는 주사기 |
| LT3892295T (lt) * | 2011-05-24 | 2023-07-10 | BioNTech SE | Individualizuotos vakcinos nuo vėžio |
| US9493532B2 (en) | 2011-12-15 | 2016-11-15 | The University Of Chicago | Compositions for cancer therapy using mutant light molecules with increased affinity to receptors |
| US9266959B2 (en) | 2012-10-23 | 2016-02-23 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using frizzled-binding agents |
| CN105073195A (zh) | 2013-02-04 | 2015-11-18 | 昂科梅德制药有限公司 | 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测 |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| CA2925104A1 (en) * | 2013-09-27 | 2015-04-02 | Vaccinogen International Partners, Lp | Autologous tumor vaccines and methods |
| EP3215165B1 (en) | 2014-11-05 | 2020-12-23 | Memorial Sloan Kettering Cancer Center | Methods of selecting t cell line and donor thereof for adoptive cellular therapy |
| US20180055920A1 (en) * | 2015-03-12 | 2018-03-01 | University Of Iowa Research Foundation | Vaccine, therapeutic composition and methods for treating or inhibiting cancer |
| EP3313419B1 (en) * | 2015-06-26 | 2020-08-19 | Memorial Sloan Kettering Cancer Center | Methods of treating cmv retinitis by t cell therapy |
| WO2017023803A1 (en) | 2015-07-31 | 2017-02-09 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| CN109068658A (zh) | 2015-11-18 | 2018-12-21 | 杜克大学 | 用于治疗癌症的肿瘤浸润淋巴细胞 |
| CA3041068A1 (en) | 2016-10-18 | 2018-04-26 | Regents Of The University Of Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
| US20200237904A1 (en) | 2017-01-26 | 2020-07-30 | Immune Therapeutics Inc. | Methods and Compositions Useful for Treating Cancer |
| WO2018224166A1 (en) | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
| JP2020530307A (ja) | 2017-06-30 | 2020-10-22 | インティマ・バイオサイエンス，インコーポレーテッド | 遺伝子治療のためのアデノ随伴ウイルスベクター |
| KR102256337B1 (ko) * | 2017-10-17 | 2021-05-26 | (주)노터스생명과학 | 조직이식을 위한 세포배양액을 포함하는 면역억제제 |
| US11446329B2 (en) | 2017-11-01 | 2022-09-20 | Restem Llc | Natural killer cell adoptive transfer therapy for the elimination of senescent PBMCs, reduction of inflammatory cytokines and treatment of IBS |
| IL259392A (en) | 2018-05-15 | 2018-08-01 | Yeda Res & Dev | Vaccination with cancer neoantigens |
| FR3082730B1 (fr) * | 2018-06-21 | 2022-04-22 | Med Inn Pharma | Methode de resolution de l'inflammation pro-tumorale a l'aide d'une preparation pharmaceutique |
| WO2023196232A1 (en) * | 2022-04-04 | 2023-10-12 | University Of Florida Research Foundation, Inc. | Method of characterizing tumors |
| CN114984199A (zh) * | 2022-04-19 | 2022-09-02 | 苏州尔生生物医药有限公司 | 一种基于癌症特异性t细胞的细胞系统、淋巴细胞药物及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3965597A (en) * | 1996-07-25 | 1998-02-20 | Regents Of The University Of California, The | Cancer immunotherapy using autologous tumor cells combined with allogeneic cytokine-secreting cells |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5192537A (en) | 1984-03-30 | 1993-03-09 | Cellcor Inc. | Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine |
| US4828991A (en) | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
| JP2639835B2 (ja) * | 1988-11-30 | 1997-08-13 | 有限会社ジオリサーチ | 免疫記憶細胞懸濁液の調製方法 |
| US5229115A (en) * | 1990-07-26 | 1993-07-20 | Immunex Corporation | Adoptive immunotherapy with interleukin-7 |
| JPH06121672A (ja) * | 1992-10-13 | 1994-05-06 | Cellcor Inc | 免疫反応性細胞の製造 |
| US5820872A (en) * | 1992-11-18 | 1998-10-13 | Yale University | Methods and compositions for improving the effectiveness of X-irradiation therapy for the treatment of an internal solid tumor |
| WO1994020120A1 (en) | 1993-03-12 | 1994-09-15 | Cellcor, Inc. | In vitro assay measuring degree of activation of immune cells |
| CA2178950A1 (en) | 1993-12-14 | 1995-06-22 | Yajun Guo | Tumor cell fusions and methods for use of such tumor cell fusions |
| US5759535A (en) | 1994-05-13 | 1998-06-02 | Research Corporation Technologies, Inc. | Immunotherapeutic strategies for the treatment of cancer |
| CA2192655A1 (en) * | 1994-06-14 | 1995-12-21 | Edgar G. Engleman | Methods for in vivo t cell activation by antigen-pulsed dendritic cells |
| DE4431401A1 (de) | 1994-08-24 | 1996-02-29 | Max Delbrueck Centrum | Lebendvakzine gegen Tumorerkrankungen |
| BR9607894A (pt) * | 1995-03-17 | 1999-06-01 | Univ California | Processo para tratar tumores |
-
1997
- 1997-10-10 AU AU48242/97A patent/AU743855B2/en not_active Ceased
- 1997-10-10 WO PCT/US1997/018718 patent/WO1998016238A2/en not_active Ceased
- 1997-10-10 CN CN97199908A patent/CN1237909A/zh active Pending
- 1997-10-10 JP JP51780398A patent/JP2001509135A/ja not_active Ceased
- 1997-10-10 CA CA002267157A patent/CA2267157C/en not_active Expired - Fee Related
- 1997-10-10 BR BR9712988-7A patent/BR9712988A/pt not_active Application Discontinuation
- 1997-10-10 EP EP97910999A patent/EP0930887B1/en not_active Expired - Lifetime
- 1997-10-10 DE DE69718029T patent/DE69718029T2/de not_active Expired - Lifetime
- 1997-10-10 KR KR1019990703176A patent/KR20000049096A/ko not_active Withdrawn
- 1997-10-10 US US08/948,939 patent/US6207147B1/en not_active Expired - Lifetime
- 1997-10-10 AT AT97910999T patent/ATE229810T1/de not_active IP Right Cessation
- 1997-10-13 AR ARP970104701A patent/AR004445A1/es not_active Application Discontinuation
-
1999
- 1999-04-09 NO NO991691A patent/NO991691L/no not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3965597A (en) * | 1996-07-25 | 1998-02-20 | Regents Of The University Of California, The | Cancer immunotherapy using autologous tumor cells combined with allogeneic cytokine-secreting cells |
Non-Patent Citations (1)
| Title |
|---|
| CROWLEY ET.AL., CANCER RESEARCH (50), 1 FEB 1990 PP492-498 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998016238A3 (en) | 1998-09-11 |
| CA2267157A1 (en) | 1998-04-23 |
| CN1237909A (zh) | 1999-12-08 |
| DE69718029T2 (de) | 2003-10-16 |
| BR9712988A (pt) | 2000-10-24 |
| DE69718029D1 (de) | 2003-01-30 |
| US6207147B1 (en) | 2001-03-27 |
| ATE229810T1 (de) | 2003-01-15 |
| NO991691L (no) | 1999-06-09 |
| AU4824297A (en) | 1998-05-11 |
| EP0930887B1 (en) | 2002-12-18 |
| NO991691D0 (no) | 1999-04-09 |
| EP0930887A2 (en) | 1999-07-28 |
| AR004445A1 (es) | 1998-12-16 |
| JP2001509135A (ja) | 2001-07-10 |
| WO1998016238A2 (en) | 1998-04-23 |
| CA2267157C (en) | 2005-05-31 |
| KR20000049096A (ko) | 2000-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU743855B2 (en) | Cancer immunotherapy using tumor cells combined with mixed lymphocytes | |
| US6277368B1 (en) | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine | |
| EP1225870B1 (en) | Composition and method of cancer antigen immunotherapy | |
| US7361332B2 (en) | Treating tumors using implants comprising combinations of allogeneic cells | |
| US6203787B1 (en) | Treating tumors using implants comprising combinations of allogeneic cells | |
| CA2346735C (en) | Cancer immunotherapy using allostimulated cells in a multiple sequential implantation strategy | |
| EP1248836B1 (en) | Method for preparing vaccines by using hybrid cells | |
| US6368593B1 (en) | Enhanced immunogenic cell populations prepared using H2 receptor antagonists | |
| US20040022813A1 (en) | Shed antigen vaccine with dendritic cells adjuvant | |
| US20070212338A1 (en) | Hybrid cells | |
| AU2018283319A1 (en) | Materials and methods for increasing immune responses | |
| O'Neill et al. | Immunotherapeutic potential of dendritic cells generated in long term stroma-dependent cultures | |
| MXPA99003341A (en) | Cancer immunotherapy using tumor cells combined with mixed lymphocytes | |
| US20090087450A1 (en) | Combination therapy of hybrid cells with BCG injection for treating Cancer Patients | |
| US20080220025A1 (en) | Treating Tumors Using Implants Comprising Combinations of Allogeneic Cells | |
| CN101855549A (zh) | 在免疫豁免部位内治疗肿瘤的方法 | |
| Marits et al. | Sentinel node-based immunotherapy of colon cancer | |
| Parney | Human glioma immunology and immunogene therapy. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |